GlaxoSmithKline
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 871
- Registration Number
- NCT05630820
- Locations
- π¬π§
GSK Investigational Site, Plymouth, United Kingdom
Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults
Phase 1
Recruiting
- Conditions
- Interventions
- Biological: TYP03A Low Dose adjuvanted investigational vaccineBiological: TYP03B Full Dose adjuvanted investigational vaccineBiological: Sanofi Pasteur's Typhoid Vi polysaccharide vaccineBiological: TYP04A Low Dose without adjuvant investigational vaccineBiological: TYP04B Full Dose without adjuvant investigational vaccineBiological: GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 96
- Registration Number
- NCT05613205
- Locations
- π§πͺ
GSK Investigational Site, Wilrijk, Belgium
A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 140
- Registration Number
- NCT05602025
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 38
- Registration Number
- NCT05590338
- Locations
- πΊπΈ
GSK Investigational Site, Las Vegas, Nevada, United States
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1544
- Registration Number
- NCT05590403
- Locations
- πͺπΈ
GSK Investigational Site, Vigo, Spain
Phase 2b Study of GSK4532990 in Adults With NASH
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 271
- Registration Number
- NCT05583344
- Locations
- π¬π§
GSK Investigational Site, Nottingham, United Kingdom
Managed Access Program for Momelotinib in Myelofibrosis
- Conditions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT05582083
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1045
- Registration Number
- NCT05568797
- Locations
- π¬π§
GSK Investigational Site, Peterborough, United Kingdom
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 340
- Registration Number
- NCT05565378
- Locations
- π¬π§
GSK Investigational Site, Wolverhampton, United Kingdom
A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years
Phase 1
Active, not recruiting
- Conditions
- Interventions
- Biological: GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant systemCombination Product: GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxideBiological: GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant systemBiological: GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1Biological: GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 122
- Registration Number
- NCT05561673
- Locations
- π¬π§
GSK Investigational Site, Cambridge, United Kingdom
Β© Copyright 2024. All Rights Reserved by MedPath